CatalYm has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy targeting Growth Differentiation Factor 15 (GDF-15).
Pfizer has paid $200 million to buy 9.9% of Hong Kong-listed cancer biotech CStone, beginning a strategic collaboration that will see the big US pharma gain rights to the company’s immunoth
Immuno-oncology has seen some striking clinical advances in the 10 years since the approval of the first therapeutic cancer vaccine, but it’s a field that doesn’t stand still.
AstraZeneca has announced an immuno-oncology collaboration with US biotech Seres Therapeutics, which will focus on increasing understanding of the gut microbiome in order to increase effica
US-based Merck & Co is putting further pressure on its arch-rival Bristol-Myers Squibb with a potential new six-week dosing schedule for some European patients taking its Keytruda (pemb